Abstract
Parathyroid hormone (PTH) paradoxically causes net bone loss (resorption) when administered in a continuous fashion, and net bone formation (deposition) when administered intermittently. Currently no pharmacological formulations are available to promote bone formation, as needed for the treatment of osteoporosis. The paradoxical behavior of PTH confuses endocrinologists, thus, a model bone resorption or deposition dependent on the timing of PTH administration would de-mystify this behavior and provide the basis for logical drug formulation. We developed a mathematical model that accounts for net bone loss with continuous PTH administration and net bone formation with intermittent PTH administration, based on the differential effects of PTH on the osteoblastic and osteoclastic populations of cells.
Bone, being a major reservoir of body calcium, is under the hormonal control of PTH. The overall effect of PTH is to raise plasma levels of calcium, partly through bone resorption. Osteoclasts resorb bone and liberate calcium, but they lack receptors for PTH. The preosteoblastic precursors and preosteoblasts possess receptors for PTH, upon which the hormone induces differentiation from the precursor to preosteoblast and from the preosteoblast to the osteoblast. The osteoblasts generate IL-6; IL-6 stimulates preosteoclasts to differentiate into osteoclasts. We developed a mathematical model for the differentiation of osteoblastic and osteoclastic populations in bone, using a delay time of 1 hour for differentiation of preosteoblastic precursors into preosteoblasts and 2 hours for the differentiation of preosteoblasts into osteoblasts. The ratio of the number of osteoblasts to osteoclasts indicates the net effect of PTH on bone resorption and deposition; the timing of events producing the maximum ratio would induce net bone deposition.
When PTH is pulsed with a frequency of every hour, the preosteoblastic population rises and decreases in nearly a symmetric pattern, with 3.9 peaks every 24 hours, and 4.0 peaks every 24 hours when PTH is administered every 6 hours. Thus, the preosteoblast and osteoblast frequency depends more on the nearly constant value of the PTH, rather than on the frequency of the PTH pulsations. Increasing the time delay gradually increases the mean value for the number of osteoblasts. The osteoblastic population oscillates for all intermittent administrations of PTH and even when the PTH infusion is constant. The maximum ratio of osteoblasts to osteoclasts occurs when PTH is administered in pulses of every 6 hours.
The delay features in the model bear most of the responsibility for the occurrence of these oscillations, because without the delay and in the presence of constant PTH infusions, no oscillations occur. However, with a delay, under constant PTH infusions, the model generates oscillations. The osteoblast oscillations express limit cycle behavior. Phase plane analysis show simple and complex attractors. Subsequent to a disturbance in the number of osteoblasts, the osteoblasts quickly regain their oscillatory behavior and cycle back to the original attractor, typical of limit cycle behavior. Further, because the model was constructed with dissipative and nonlinear features, one would expect ensuing oscillations to show limit cycle behavior. The results from our model, increased bone deposition with intermittent PTH administration and increased bone resorption with constant PTH administration, conforms with experimental observations and with an accepted explanation for osteoporosis.
Similar content being viewed by others
References
Brown, E. M. (1991). Extracellular Ca2+ sensing, regulation of parathyroid cell function, and role of Ca2+ and other ions as extracellular (first) messengers. Physiol. Rev. 71, 371–411.
Burgess, T. L. et al. (1999). The ligand for osteoprotegerin (OPGL) directly activates mature osteoclasts. J. Cell Biol. 145, 527–538.
Cantor, C. R. and P. R. Schimmel (1971). Biophysical Chemistry, Part III, The Behavior of Biological Macromolecules, San Francisco: W.H. Freeman & Co., pp. 849–866.
Dempster, D. W., F. Cosman, M. Parisien, V. Shen and R. Lindsay (1993). Anabolic actions of parathyroid hormone on bone. Endocr. Rev. 14, 690–709.
Dobnig, H. and R. T. Turner (1995). Evidence that intermittent treatment with parathryoid hormone increases bone formation in adult rat by activation of bone lining cells. Endocrinology 136, 3632–3638.
Finkelstein, J. S., A. Klibanski, A. L. Arnold, T. L. Toth, M. D. Hornstein and R. M. Neer (1998). Prevention of estrogen deficiency-related bone loss with human parathyroid hormone (1–34). J. Am. Med. Assoc. 280, 1067–1073.
Granner, D. K. (1995). Hormonal action, in Principles and Practice of Endocrinology and Metabolism, 2nd edn, K. L. Becker (Ed.), Philadelphia: J. P. Lippincott Co., pp. 20–25.
Green, J., S. Schotland, Z. Sella and C. R. Kleeman (1994). Interleukin-6 attenuates agonist-mediated calcium mobilization in murine osteoblasts. J. Clin. Invest. 93, 2340–2350.
Greenfield, E. M., S. A. Gornik, M. C. Horowitz, H. J. Donahue and S. M. Shaw (1993). Regulation of cytokine expression in osteoblasts by parathyroid hormone: rapid stimulation of interleukin-6 and leukemia inhibitory factor mRNA. J. Bone Mineral Res. 8, 1163–1171.
Harms, H. M., U. Kaptaina, W. R. Kulpmann, G. Brabrant and R. D. Hesch (1989). Pulse amplitude and frequency modulation of parathyroid hormone in plasma. J. Clin. Endocrinol. Metab. 69, 843–851.
Hesch, R. D. (1988). Pulsatile secretion of parathyroid hormone and its action on a Type I and Type II PTH receptor: a hypothesis for understanding osteoporosis. Calcif. Tissue. Int. 42, 341–344.
Hock, J. M. and I. Gera (1992). Effects of continuous and intermittent administration and inhibition of resorption on the anabolic response of bone to parathyroid hormone. J. Bone Mineral Res. 7, 65–72.
Horwood, N. J., J. Elliott, T. J. Martin and M. T. Gillespie (1998). Osteotropic agents regulate the expression of osteoclast differentiation factor and osteoprotegerin in osteoblastic stromal cells. Endocrinology 139, 4743–4746.
Hughes, F. J. and G. L. Howells (1993). Interleukin-6 inhibits bone formation in vitro. Bone Miner. 21, 21–28.
Hurley, M. M., S. Tetradis, Y.-F. Huang, J. Hock, B. E. Kream, L. G. Raisz and M. G. Sabbieti (1999). Parathyroid hormone regulates the expression of fibroblast growth factor-2 mRNA and fibroblast growth factor receptor mRNA in osteoblastic cells. J. Bone Miner. Res. 14, 776–783.
Ishizuya, T., S. Yokose, M. Hori, T. Noda, T. Suda, S. Yoshiki and A. Yamaguchi (1997). Parathyroid hormone exerts disparate effects on osteoblast differentiation depending on exposure time in rat osteoblastic cells. J. Clin. Invest. 99, 2961–2970.
Isogai, Y. T., T. Akatsu, T. Ishizuya, A. Yamaguchi, M. Hori, N. Tokahashi and T. Suda (1996). Parathyroid hormone regulates osteoblast differentiation positively or negatively depending on differentiation stages. J. Bone Mineral Res. 11, 1384–1393.
Jongen, I. W., E. C. Willemstein-van Hove, J. M. van der Meer, M. P. Bos, H. Juppner, G. V. Segre, A. B. Abou-Samra, J. H. Feyen and M. P. Herrmann-Erlee (1996). Down-regulation of the receptor for parathyroid hormone (PTH) and PTH-related peptide by PTH in primary fetal rat osteoblasts. J. Bone Miner. Res. 11, 1218–1225.
Kong, Y. Y. et al. (1999). OPGL is a key regulator of osteoclastogenensis, lymphocyte development and lymph-node organogenesis. Nature 397, 315–323.
Mackey, M. C. and L. Glass (1977). Oscillations and chaos in physiological control systems. Science 197, 287–289.
Mahoney, C. A., R. A. Nissenson, P. Sarnacki and K. Pua (1983). Canine renal receptors for parathyroid hormone. Down-regulation in vivo by exogenous parathyroid hormone. J. Clin. Invest. 72, 411–421.
McSheehy, P. M. J. and T. J. Chambers (1986). Osteoblastic cells mediate osteoclastic responsiveness to parathyroid hormone. Endocrinology 118, 824–828.
Mundy, G. R. (1993). Cytokines and growth factors in the regulation of bone remodeling. J. Bone Mineral Res. 8, Suppl. 2, S505–S510.
Mundy, G. R. (1999). Cellular and molecular regulation of bone turnover. Bone 24, 35S–38S.
Murray, J. D. (1989). Mathematical Biology, Berlin: Springer-Verlag, pp. 8–12.
Oniya, J. E., J. Bidwell, J. Herring, J. Hulman and J. M. Hock (1995). In vivo, human parathyroid fragment (hPTH 1-34) transiently stimulates immediate early response gene expression, but not proliferation, in trabecular bone cells of young rats. Bone 17, 479–484.
Parnas, H. (1991). Control of neurotransmitter release: use of facilitation to analyze the regulation of intracellular calcium, in Biological Kinetics, L. A. Segel (Ed.), Cambridge, U.K.: Cambridge University Press, pp. 153–181.
Peck, W. A. (1993). Concensus development conference: diagnosis, prophylaxis, and treatment of osteoporosis. Am. J. Med. 94, 646–650.
Perelson, A. S. (1991). Chaos, in Biological Kinetics, L. A. Segel (Ed.), Cambridge, U.K.: Cambridge University Press, pp. 153–181.
Podbesek, R., C. Edouard, P. J. Meunier, J. A. Parsons, J. Reeve, R. W. Stevenson and J. M. Zanelli (1983). Effects of two treatment regimes with synthetic human parathyroid hormone fragment on bone formation and the tissue balance of trabecular bone in greyhounds. Endocrinology 112, 1000–1006.
Prank, K., H. Harms, M. Daemmig, G. Brabant, F. Mitschke and R.-D. Hesch (1994). Is there low-dimensional chaos in pulsatile secretion of parathyroid hormone in normal human subjects? Am. J. Physiol. 266, E653–E658.
Raisz, L. G. (1988). Local and systemic factors in the pathogenesis of osteoporosis. N. Engl. J. Med. 318, 818–828.
Raisz, L. G. and B. E. Kream (1983). Regulation of bone formation. New Engl. J. Med. 309, 29–35.
Riggs, F. L. and L. J. Melton III (1992). The prevention and treatment of osteoporosis. N. Engl. J. Med. 327, 620–627.
Roodman, G. D. (1995). Osteoclast function in Paget’s disease and multiple myeloma. Bone 17, 57S–61S.
Rosenberg, A. (1994). Skeletal system and soft tissue tumors, in Robbins Pathologic Basis of Disease, 5th edn, R. S. Cotran, V. Kumar and S. L. Robbins (Eds), Philadelphia: W. B. Saunders Co., pp. 1219–1222.
Samuels, M. H., J. Veldhuis, C. Cawley, R. J. Urban, M. Luther, R. Bauer and G. Mundy (1993). Pulsatile secretion of parathyroid hormone in normal young subjects: assessment by deconvolution analysis. J. Clin. Endocrinol. Metab. 76, 399–403.
Suda, T., N. Takahashi and T. J. Martin (1992). Modulation of osteoclast differentiation. Endocr. Rev. 13, 66–80.
Takahashi, N., N. Udagawa and T. Suda (1999). A new member of tumor necrosis factor ligand family, ODF/OPGL/TRANCE/RANKL, regulates osteoclast differentiation and function. Biochem. Biophys. Res. Commun. 256, 449–455.
Tam, C. S., N. M. Heersche, T. M. Murray and J. A. Parsons (1982). Parathyroid hormone stimulates the bone apposition rate independentlly of its resorptive action: differential effects of intermittent and continuous administration. Endocrinology 110, 506–512.
Tohmé, J. F., F. Corman and R. Lindsay (1995). Osteoporosis, in Principles and Practice of Endocrinology and Metabolism, 2nd edn, K. L. Becker (Ed.), Philadelphia: J. B. Lippincott Co., pp. 567–585.
Weryha, G. and J. Leclère (1995). Paracrine regulation of bone remodeling. Horm. Res. 43, 69–75.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Kroll, M.H. Parathyroid hormone temporal effects on bone formation and resorption. Bull. Math. Biol. 62, 163–188 (2000). https://doi.org/10.1006/bulm.1999.0146
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1006/bulm.1999.0146